Cantor Fitzgerald, L. P. Mereo Biopharma Group PLC Transaction History
Cantor Fitzgerald, L. P.
- $2.48 Billion
- Q4 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 225,000 shares of MREO stock, worth $569,250. This represents 0.03% of its overall portfolio holdings.
Number of Shares
225,000Holding current value
$569,250% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding MREO
# of Institutions
99Shares Held
116MCall Options Held
151KPut Options Held
455K-
Janus Henderson Group PLC London, X017.1MShares$43.3 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$38.7 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$24.3 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$22 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$21.9 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $316M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...